CCDL24

CCDL24 is an innovative multitargeting small molecule therapy being developed by Cosmos Health for the treatment of various gastrointestinal (GI) disorders, including irritable bowel syndrome (IBS), Crohn's disease, and ulcerative colitis. The product utilizes advanced biopolymeric matrices derived from natural ingredients to encapsulate bioactive molecules, a delivery system designed to enhance drug efficacy and facilitate targeted delivery to specific sites within the gastrointestinal tract. Currently in the preclinical development phase, research efforts are focused on optimizing the physicochemical properties of the biopolymeric grids and evaluating the formulation's impact on gut microflora through in vitro studies and simulations. CCDL24 leverages the company's expertise in biocompatible hydrogels, building upon the technology platform used in their CCX0722 program to address unmet needs in gastrointestinal health.